BioLineRx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioLineRx and other ETFs, options, and stocks.

About BLRX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. 

CEO
Philip Adam Serlin
CEOPhilip Adam Serlin
Employees
24
Employees24
Headquarters
Modi'in, HaMerkaz
HeadquartersModi'in, HaMerkaz
Founded
2003
Founded2003
Employees
24
Employees24

BLRX Key Statistics

Market cap
13.36M
Market cap13.36M
Price-Earnings ratio
-1.31
Price-Earnings ratio-1.31
Dividend yield
Dividend yield
Average volume
8.20K
Average volume8.20K
High today
$3.10
High today$3.10
Low today
$2.80
Low today$2.80
Open price
$2.86
Open price$2.86
Volume
2.68K
Volume2.68K
52 Week high
$4.56
52 Week high$4.56
52 Week low
$2.15
52 Week low$2.15

BLRX News

TipRanks 5d
BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.